To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids

Patient has known or suspected hypersensitivity to the IMP or excipients, including lactose (Note: lactose intolerance is not an exclusion criterion).

Patient who has used systemic steroid in the 6 weeks before Visit 1.

Patient with a history of hospitalization due to asthma in the 6 months prior to Visit 1 or a history of intubation because of asthma at any time in their lifetime.

Patient with any active pulmonary disease other than asthma.

Patient non-compliant with study procedures in the Screening period (prior to randomization) -as judged by the Investigator.

Patient under treatment with biologicals such as monoclonal antibodies or chimeric biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5 half-lives before Visit 1, whichever is longer.

Patient treated with any investigational drug within 30 days (or 5 half-lives, whichever is longer) prior to Visit 1.

Patient on treatment with strong cytochrome P450 (CYP)3A4 inhibitors such as ketoconazole or itraconazole or CYP3A4 inducers such as rifampin at Visit 1 or within 14 days prior to administration of IMP.

Patient with a history, laboratory abnormality, or clinical suspicion of any clinically relevant disease or disorder, including uncontrolled hypertension or uncontrolled diabetes, which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study, or any other safety concerns in the opinion of the Investigator.

Patient with diagnosis of any kind of chronic hepatitis or known human immunodeficiency virus (HIV) infections at the time of enrolment.

Patient with any active malignancy or treatment thereof within the five years prior to enrolment.

Patient with any clinically important abnormalities in rhythm, conduction, or morphology of the screening 12-lead ECG as judged by the Investigator on the screening ECG.

Patient with prolonged QT interval using Fridericia's correction ≥ 450 msec for males and females on the screening ECG or family history of long QT syndrome.

Patient with PR (PQ) interval prolongation (\> 240 msec), intermittent second or third degree atrio-ventricular (AV) block or AV dissociation or with QRS interval ≥ 120 msec or any other ECG abnormality which might affect the evaluation of the central ECG reading on the screening ECG.

Patient with heart rate (HR) \< 45 beat per minute (bpm) or \> 90 bpm at Screening ECG.

Patient with implanted cardiac defibrillator and patients with sustained symptomatic ventricular and/or atrial tachyarrhythmia.

Patient with any contraindication against the use of sympathomimetic drugs as judged by the Investigator.

Patient with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society Class II, or a myocardial infarction, or stroke within 6 months before Visit 1.

Patient with a history of hospitalization within 12 months caused by heart failure or a diagnosis of heart failure higher than New York Heart Association (NYHA) Class II.

Patient who failed the screening procedures or patient with previous participation in the current study. Patients who failed the screening procedures may be re-screened once only.

Patient with a history of or current alcohol or drug abuse (including marijuana), as judged by the Investigator.

Patient with planned in-patient surgery, major dental procedure or hospitalization during the study.

Patient involved in the planning and/or conduct of the study (applies to both AstraZeneca staff, contract research organization (CRO) staff and/or staff at the study site).

Vulnerable person (e.g., person kept in detention).

Patient with exacerbation requiring emergency room visit or systemic steroid use or increased dose of ICS within the Screening Period

Patient who intends to use any concomitant medication not permitted by this protocol.

Patient who received live attenuated vaccine within 30 days prior to Visit 1 or who received inactivated vaccine within 7 days prior to Visit 1.

Donation or loss of \> 400 mL blood and plasma within the previous 3 months prior to Screening.

What this study is about